Dec 21, 2020 / NTS GMT
Christine Corrado - Proactive - Moderator
Hello, and thanks so much for watching Proactive New York. I'm Christine Corrado. Joining me right now is Mike Nall, CEO at Biocept. Mike, good to see you, how are you?
Mike Nall - Biocept, Inc. - President & CEO
Good, Christine.
Questions and Answers:
Christine Corrado - Proactive - ModeratorGreat to hear, Mike. Today, we're talking about how the group had results back from prospective study showing that its target selector at liquid biopsy was highly accurate in monitoring the HER2 protein. I mean, can you maybe explain first off why it's so important to be able to recognize the HER2 protein?
Mike Nall - Biocept, Inc. - President & CEO
Yeah. No, absolutely. So HER2 is a standard of care test in tissue for patients diagnosed with [breast cancer]. And in fact, it's one of the first, what we call biomarkers that was discovered and had a therapy associated with it called Herceptin. And a lot of investors have heard about
Trustpilot
